Unichem Laboratories Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Pabitrakumar Bhattacharyya

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	5.9yrs
Promedio de permanencia en la Junta Directiva	less than a year

Actualizaciones recientes de la dirección

Recent updates

CEO

Pabitrakumar Bhattacharyya (54 yo)

less than a year

Permanencia

Mr. Pabitrakumar Kalipada Bhattacharyya serves as a Managing Director and Director at Unichem Laboratories Limited since August 10, 2023. Mr. Bhattacharyya brings rich experience from organizations like Su...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Sandip Ghume	Deputy Chief Financial Officer	no data	₹10.75m	sin datos
Pradeep Bhandari	Head of Legal & Company Secretary	4.8yrs	₹9.66m	sin datos
Pabitrakumar Bhattacharyya	MD & Director	less than a year	sin datos	sin datos
Jalesh Burye	Chief Quality & Compliance Officer	no data	sin datos	sin datos
Prasad Joshi	Vice President of Human Resources & ER	15.9yrs	₹7.48m	sin datos
Vinod Behl	Head of Projects & Investments	no data	₹2.10m	sin datos
Dhananjay Sathe	Chief Scientific & Compliance Officer	no data	sin datos	sin datos
Ashwani Kumar	Chief Manufacturing & Compliance Officer	no data	sin datos	sin datos
Bhagwat Dhingra	Chief Executive of Domestic Pharma	11.8yrs	₹13.62m	sin datos
Scott Delaney	President of North America & CEO of North America	5.9yrs	sin datos	sin datos
P. Deshpande	Vice President of Chemical of Research and Development	no data	₹593.35k	sin datos
Supriya Mody	Associate Vice President of International Business	no data	₹3.82m	1.35% ₹ 570.9m

5.9yrs

Permanencia media

65yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 506690 es experimentado (5.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Pabitrakumar Bhattacharyya	MD & Director	less than a year	sin datos	sin datos
Prakash Mody	Chairman	49.9yrs	₹59.24m	16.21% ₹ 6.9b
Arun Todarwal	Independent Director	no data	sin datos	sin datos
Pranay Godha	Non-Executive Non-Independent Director	less than a year	sin datos	sin datos
Priti Puri	Additional Independent Non-Executive Director	1.2yrs	sin datos	sin datos
Anand Kurse	Independent Director	no data	sin datos	sin datos

1.0yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de 506690 no se considera experimentada (0.9 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Unichem Laboratories Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Insider recently sold ₹1.5m worth of stock

Non-Executive Independent Director recently sold ₹10m worth of stock

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: EPS: ₹11.93 (vs ₹9.08 loss in 3Q 2023)

Unichem Laboratories Limited to Report Q3, 2024 Results on Feb 05, 2024

Unichem Laboratories Limited Receives Anda Approval for Its Doxazosin Tablets USP, 1 Mg, 2 Mg, 4 Mg and 8 Mg

Second quarter 2024 earnings released: ₹3.48 loss per share (vs ₹10.04 loss in 2Q 2023)

Unichem Laboratories Limited to Report Q2, 2024 Results on Nov 01, 2023

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Insider recently sold ₹1.5m worth of stock

First quarter 2024 earnings released: ₹0.09 loss per share (vs ₹3.32 loss in 1Q 2023)

Non-Executive Independent Director recently sold ₹10m worth of stock

Full year 2023 earnings released: ₹28.72 loss per share (vs ₹4.70 profit in FY 2022)

Third quarter 2023 earnings released: ₹9.08 loss per share (vs ₹2.01 loss in 3Q 2022)

Krka Reportedly Eyes Promoter Stake in Unichem Laboratories

Insufficient new directors

Second quarter 2023 earnings released: ₹10.04 loss per share (vs ₹1.82 loss in 2Q 2022)

Unichem Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Unichem Laboratories Limited Receives ANDA Approval for Extended Phenytoin Sodium Capsules USP, 100 Mg from United States Food and Drug Administration

Unichem Laboratories Limited Receives ANDA Approval for Carbamazepine Tablets USP

Unichem Laboratories Limited Receives ANDA Approval for Its Quetiapine Extended-Release Tablets

Unichem Laboratories Limited Receives ANDA Approval for its Labetalol Hydrochloride Tablets, USP 100 Mg, 200 Mg, and 300 Mg from the United States Food and Drug Administration

Unichem Laboratories Limited to Report Q1, 2023 Results on Aug 09, 2022

Upcoming dividend of ₹4.00 per share

Full year 2022 earnings released: EPS: ₹4.70 (vs ₹4.88 in FY 2021)

Unichem Laboratories Limited, Annual General Meeting, Aug 09, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Unichem Laboratories Limited Recommends Final Dividend for the Year Ended March 31, 2022

Unichem Laboratories Limited to Report Q4, 2022 Results on May 27, 2022

Insufficient new directors

Unichem Laboratories Limited Receives ANDA Approval for Its Divalproex Sodium Extended-Release Tablet

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings released: ₹1.82 loss per share (vs ₹1.24 profit in 2Q 2021)

Upcoming dividend of ₹4.00 per share

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Receives Tentative USFDA Approval for ANDA of Aripiprazole Tablets

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Recommends Dividend for the Year Ended March 31, 2021

Unichem Laboratories Limited Announces That It Has Received ANDA Approval for its Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg

Insider recently bought ₹2.3m worth of stock

Unichem Laboratories Limited Receives ANDA Approval for Its Guanfacine Tablets, USP 1 Mg and 2 Mg from the United States Food and Drug Administration

New 90-day high: ₹332

Unichem Laboratories Limited Receives Anda Approval for Its Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg from the United States Food and Drug Administration

New 90-day high: ₹294

Third quarter 2021 earnings released: EPS ₹3.35 (vs ₹2.07 loss in 3Q 2020)

Unichem Laboratories Limited Receives ANDA Approval for its Zonisamide Capsules, USP 25 mg, 50 mg and 100 mg from USFDA

Unichem Laboratories Limited to Report Q3, 2021 Results on Jan 30, 2021

New 90-day high: ₹286

Unichem Laboratories Limited Receives ANDA Approval from USFDA for Unichem's Celecoxib Capsules, 50 Mg, 100 Mg, 200 Mg, and 400 Mg

New 90-day high: ₹285

Unichem Laboratories Limited Receives ANDA Approval for Atenolol and Chlorthalidone Tablet

New 90-day low: ₹237

Second quarter 2021 earnings released: EPS ₹1.24

First half earnings released

Upcoming Dividend of ₹4.00 Per Share

First quarter earnings released

New 90-day high - ₹214

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad